

ongoing trials - trial from other registries

Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF - PHASE2 - RECRUITING

Code: NCT06468527 **Year:** 2024 **Date:** 2024

Author: Kors van der Ent

Participants

Adults with CF and two well-characterized genetic mutations in the CFTR gene, persistent airways PA infection

Interventions

Colistimethate Sodium (CMS) 4 MIU: vials of CMS 4 MIU (320 mg CMS) are reconstituted with 8 mL 0,9% saline solution, once daily, administered by inhalation via a nebuliser for 28 days

Outcome measures

Primary outcomes: number of observed safety events during the 28-day treatment period in each treatment arm[The tolerability and safety will be assessed based on all reported adverse events (ie dyspnoea, bronchoconstriction, cough, wheezing) , clinical laboratory test results, vital signs measurements, electrocardiogram findings, physical examination findings and spirometry results, or clinically significant changes thereof.

<https://ClinicalTrials.gov/show/NCT06468527>

Keywords

Anti-Bacterial Agents; Bacterial Infections; colistimethate; Colistin; Infection; Inhalation OR nebulised; pharmacological_intervention; Powders; Pseudomonas aeruginosa; Pseudomonas; Respiratory Tract Diseases; Respiratory Tract Infections; other anti-bacterial agents;